Quibim partners with Germany’s Vara to bring Europe’s leading breast-cancer screening AI to Spain
- Vara’s AI has demonstrated a 16.7% increase in breast-cancer detection and is already used in 50% of Germany’s national screening program.
- The agreement will help reduce the clinical workload of Spanish radiologists by introducing a proven tool that improves early detection and alleviates pressure at a time of specialist shortages.
- Quibim is developing a complete breast-cancer ecosystem that will integrate Vara’s screening AI with its own MRI-based diagnostic solution, QP-Breast®, now in its final development phase.
14 April 2026 — Quibim, a Spanish leader in artificial intelligence applied to medical imaging, and Vara, the most widely deployed AI platform in organized breast-cancer screening programs in Europe, have entered into an exclusive strategic partnership to bring to Spain the most advanced AI infrastructure for population-based mammography screening.
European screening programmes are under increasing pressure due to an ageing workforce, an expanding eligible population and the unsustainability of double human reading. This agreement comes at a crucial moment to ensure the sustainability and quality of large-scale screening.
This collaboration enables Quibim to reinforce its dedication to the Spanish healthcare system by providing tools that enhance early detection and alleviate radiologists’ workload.
Quibim is working to provide the healthcare system with a comprehensive breast cancer solution ecosystem, integrating Vara’s screening tool with its own QP Breast® solution for advanced MRI-based diagnostics, which is currently in its final development phase.
AI that improves breast cancer detection by 16.7%
A recent study involving 460,000 women and published in Nature Medicine and demonstrated that Vara’s AI mammography system increases cancer detection rates by 16.7%, reduces unnecessary follow-up examinations due to false positives by 15%, and decreases radiologists’ workload by 60%.
Vara also holds CE certification as an ‘independent second reader’, meaning it could replace the second radiologist in double-reading screening programmes while maintaining the quality standards required by European regulations.
According to Ángel Alberich Bayarri, Quibim’s CEO and founder, “Spanish radiologists need tools that allow them to focus on the most complex cases and reduce clinical pressure now more than ever. By incorporating Vara for mammography and combining it with our QP Breast® MRI tool, we strengthen our position as a leader in oncology — where we are already a reference in prostate cancer — and provide hospitals with the breast cancer AI technology backed by the strongest clinical evidence worldwide across the two most widely used techniques: mammography and MRI, from screening to diagnosis. This agreement marks a decisive step towards improving screening quality and strengthening the diagnostic capacity of the Spanish healthcare system.”
Jonas Muff, founder and CEO of Vara, adds: “Breast cancer screening is one of the most impactful healthcare priorities – but it only works if programs can sustain the capacity to serve every woman at high quality. That is exactly where the pressure is building across Europe and in Spain. Vara exists to make screening programs more effective and more sustainable while also increasing quality. With Quibim’s deep expertise in Spain’s healthcare system, we can now bring that same proven infrastructure to Spanish screening programs.”
A strategic Alliance
Under the agreement, Quibim will be responsible for the deployment and commercialisation of Vara’s platform, as well as providing the first level of support. This platform processes 50% of all mammograms in Germany’s national screening programme and has already analysed more than 6.1 million studies.
Combining both companies’ technologies will create a comprehensive breast care ecosystem offering highly efficient and precise population screening with Vara and advanced diagnosis and deep characterisation with Quibim’s QP Breast®, which is currently in its final development stage. This integration will enable Spanish healthcare systems to transition to a continuous model of breast cancer prevention, detection and personalised management.
Spanish innovation with global reach
Founded in Valencia nearly a decade ago, Quibim is one of Europe’s most advanced companies in quantitative medical imaging analysis. It has a presence in almost 200 medical and research centres across the European Union, the United States, the United Kingdom, South America, Australia, and Japan.
Quibim’s algorithms analyse medical images, such as MRIs, CTs, and PETs, and extract information that is often invisible to the human eye. This enables the detection and diagnosis of diseases and lesions, as well as providing a deeper understanding of their biological behaviour.
Quibim has several solutions certified by regulatory authorities in Europe and the United States, but its flagship product is QP Prostate®, which is dedicated to screening for and diagnosing aggressive prostate cancer. Just a few months ago, the UK’s National Health Service (NHS) announced that Quibim’s technology would be incorporated into a pilot project assessing the impact of AI on early diagnosis in hospitals across different regions.
In addition to prostate cancer, Quibim offers advanced solutions for optimising the diagnosis of neurodegenerative diseases through brain MRI (QP Brain®) and liver diseases (QP Liver®).
About Quibim
Quibim is a Spanish company that designs pioneering tools to leverage imaging data and improve patient outcomes. With offices in New York (USA), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was founded with the ambition of turning imaging into a catalyst for precision medicine. Quibim leads imaging biomarker research in the life sciences, developing advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company uses MRI, CT, and PET to create regulatory-approved medical devices seamlessly integrated into clinical workflows worldwide. More information at quibim.com
About Vara
Vara is the AI for the future of European breast cancer screening. The Berlin-based company powers approximately 50% of Germany’s national screening program – the largest AI deployment in an organized screening program worldwide. Its PRAIM study, published in Nature Medicine, is the world’s largest prospective evaluation of AI in breast cancer screening, demonstrating improved cancer detection and reduced false recalls simultaneously. Vara holds the only CE mark (Class IIb, MDR) for independent AI reading in mammography and is the only vendor offering continuous real-time AI performance monitoring. The company works with distribution partners across 10+ European countries. For more information, visit vara.ai